Maria De Angioletti 

Dr. De Angioletti earned her B.Sc. in Biology and her Board Certification in General Pathology at the University of Naples. She subsequently joined the IGB-CNR in Naples, where she investigated the molecular basis of inherited anemias and the molecular epidemiology of thalassemia. Driven by her interest in human genetic diseases, she joined the Department of Human Genetics at Memorial Sloan-Kettering Cancer Center in New York, conducting research on retrovirally mediated gene transfer in primitive hematopoietic stem cells across various animal models (mouse, macaque, and human xenografts in immune-deficient mice) and providing novel insights into the risk of mutagenesis associated with retrovirally transferred transgenes. In 2001she expanded her scientific focus to clonal disorders and the influence of individual genetic variability on disease predisposition, prognosis, and therapeutic outcomes: including studies on CTLA4 in systemic sclerosis, P450 family genes in breast cancer endocrine therapy, and UGT1A variants in irinotecan response.

Currently, Dr. De Angioletti is First Researcher at the ICCOM-CNR and Guest Group Leader at the Core Research Laboratory of ISPRO, Florence. Her research focuses primarily on the molecular mechanisms underlying prostate cancer pathogenesis and the rare hematological disorder paroxysmal nocturnal hemoglobinuria (PNH). Her research group explores two major biomedical areas: (1) the role of ETS transcription factors in prostate cancer pathogenesis, with a focus on ETV4 (including its role in cell proliferation, epithelial-mesenchymal transition, downstream target identification, and interaction with PTEN loss); and (2) the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria (PNH), including the investigation of anti-complement therapies. Furthermore, her group investigates the impact of ETS transcription factor overexpression on the tumor microenvironment and the expression of various immune checkpoints.  ORCID ID: orcid.org/0000-0002-2686-6457